What is claimed:

1. Use of a MEK inhibitor which is binimetinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer, wherein the medicament is to be used in combination with a PD-1 binding antagonist.

2. Use of a MEK inhibitor which is binimetinib or a pharmaceutically acceptable salt thereof, and a PD-1 binding antagonist in the manufacture of a medicament for treating cancer,

3. The use of claim 1 or claim 2, wherein said cancer is colorectal cancer or pancreatic cancer.

4. The use of claim 3, wherein said cancer is metastatic colorectal cancer.

5. The use of claim 4, wherein said colorectal cancer is metastatic microsatellite stable colorectal cancer.

6. The use of claim 1 or claim 2, wherein the cancer is pancreatic cancer.

7. The use of any one of claims 1 to 6, wherein the PD-1 binding antagonist is an anti PD-1 antibody.

8. The use of claim 7, wherein the anti PD-1 antibody is nivolumab or a biosimilar thereof.

9. The use of claim 7, wherein the anti PD-1 antibody is pembrolizumab or a biosimilar thereof.

10. The use according to any one of claims 1-9, wherein the MEK inhibitor is crystallized binimetinib.

11. A pharmaceutical drug consisting essentially of
a MEK inhibitor, which is binimetinib or a pharmaceutically acceptable salt thereof; and
a PD-1 binding antagonist.

12. A pharmaceutical combination of drugs consisting essentially of
a MEK inhibitor, which is binimetinib or a pharmaceutically acceptable salt thereof; and

a PD-1 binding antagonist

which are to be used sequentially.

13. The pharmaceutical drug or drugs according to claim 11 or claim 12, wherein the PD-1 binding antagonist is an anti PD-1 antibody.

14. The pharmaceutical drug or drugs according to claim 13, wherein the anti PD-1 antibody is nivolumab or a biosimilar thereof.

15. The pharmaceutical drug or drugs according to claim 13, wherein the anti PD-1 antibody is pembrolizumab or a biosimilar thereof.

16. The pharmaceutical drug or drugs according to any one of claims 11-15, wherein said MEK inhibitor is formulated as a tablet.

17. The pharmaceutical drug or drugs according to claim 16, wherein said tablet comprises 15 mg of said MEK inhibitor.

18. Binimetinib for use in treating cancer, wherein during treatment, a PD-1 binding antagonist is also to be used independently of the binimetinib.

19. Binimetinib, in combination with a PD-1 binding antagonist, for use in the treatment of cancer.

20. A kit comprising binimetinib for use in combination with a PD-1 binding antagonist.